Lei Zhu
Chairman at Beijing Shenogen Pharma Group Ltd.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Kun Meng | M | 61 |
Beijing Shenogen Pharma Group Ltd.
 Beijing Shenogen Pharma Group Ltd. Pharmaceuticals: MajorHealth Technology Beijing Shenogen Pharma Group Co. Ltd. engages in the manufacture of icaritin drug products. It focuses on the treatment of multiple malignant tumors such as hepatocellular carcinoma, breast cancer, non-small cell lung cancer, and lymphoma. The company was founded by Kun Meng and Zhao Yi Wang on May 5, 2008 and is headquartered in Beijing, China. | 18 years |
| Zhao Yi Wang | M | 65 |
Beijing Shenogen Pharma Group Ltd.
Beijing Shenogen Pharma Group Ltd. Pharmaceuticals: MajorHealth Technology Beijing Shenogen Pharma Group Co. Ltd. engages in the manufacture of icaritin drug products. It focuses on the treatment of multiple malignant tumors such as hepatocellular carcinoma, breast cancer, non-small cell lung cancer, and lymphoma. The company was founded by Kun Meng and Zhao Yi Wang on May 5, 2008 and is headquartered in Beijing, China. | 18 years |
| Larry Zhang | M | - |
Beijing Shenogen Pharma Group Ltd.
Beijing Shenogen Pharma Group Ltd. Pharmaceuticals: MajorHealth Technology Beijing Shenogen Pharma Group Co. Ltd. engages in the manufacture of icaritin drug products. It focuses on the treatment of multiple malignant tumors such as hepatocellular carcinoma, breast cancer, non-small cell lung cancer, and lymphoma. The company was founded by Kun Meng and Zhao Yi Wang on May 5, 2008 and is headquartered in Beijing, China. | - |
| Yan Min Tang | F | 51 |
Beijing Shenogen Pharma Group Ltd.
Beijing Shenogen Pharma Group Ltd. Pharmaceuticals: MajorHealth Technology Beijing Shenogen Pharma Group Co. Ltd. engages in the manufacture of icaritin drug products. It focuses on the treatment of multiple malignant tumors such as hepatocellular carcinoma, breast cancer, non-small cell lung cancer, and lymphoma. The company was founded by Kun Meng and Zhao Yi Wang on May 5, 2008 and is headquartered in Beijing, China. | 5 years |
| Xu Tian | F | 64 |
Beijing Shenogen Pharma Group Ltd.
Beijing Shenogen Pharma Group Ltd. Pharmaceuticals: MajorHealth Technology Beijing Shenogen Pharma Group Co. Ltd. engages in the manufacture of icaritin drug products. It focuses on the treatment of multiple malignant tumors such as hepatocellular carcinoma, breast cancer, non-small cell lung cancer, and lymphoma. The company was founded by Kun Meng and Zhao Yi Wang on May 5, 2008 and is headquartered in Beijing, China. | 5 years |
| Shu Xue Wang | M | 48 |
Beijing Shenogen Pharma Group Ltd.
Beijing Shenogen Pharma Group Ltd. Pharmaceuticals: MajorHealth Technology Beijing Shenogen Pharma Group Co. Ltd. engages in the manufacture of icaritin drug products. It focuses on the treatment of multiple malignant tumors such as hepatocellular carcinoma, breast cancer, non-small cell lung cancer, and lymphoma. The company was founded by Kun Meng and Zhao Yi Wang on May 5, 2008 and is headquartered in Beijing, China. | 9 years |
| Jun Xie | M | 55 |
Beijing Shenogen Pharma Group Ltd.
Beijing Shenogen Pharma Group Ltd. Pharmaceuticals: MajorHealth Technology Beijing Shenogen Pharma Group Co. Ltd. engages in the manufacture of icaritin drug products. It focuses on the treatment of multiple malignant tumors such as hepatocellular carcinoma, breast cancer, non-small cell lung cancer, and lymphoma. The company was founded by Kun Meng and Zhao Yi Wang on May 5, 2008 and is headquartered in Beijing, China. | 5 years |
| Jun Fei Feng | M | 41 |
Beijing Shenogen Pharma Group Ltd.
Beijing Shenogen Pharma Group Ltd. Pharmaceuticals: MajorHealth Technology Beijing Shenogen Pharma Group Co. Ltd. engages in the manufacture of icaritin drug products. It focuses on the treatment of multiple malignant tumors such as hepatocellular carcinoma, breast cancer, non-small cell lung cancer, and lymphoma. The company was founded by Kun Meng and Zhao Yi Wang on May 5, 2008 and is headquartered in Beijing, China. | 5 years |
| Jian Guang Li | M | 59 |
Beijing Shenogen Pharma Group Ltd.
Beijing Shenogen Pharma Group Ltd. Pharmaceuticals: MajorHealth Technology Beijing Shenogen Pharma Group Co. Ltd. engages in the manufacture of icaritin drug products. It focuses on the treatment of multiple malignant tumors such as hepatocellular carcinoma, breast cancer, non-small cell lung cancer, and lymphoma. The company was founded by Kun Meng and Zhao Yi Wang on May 5, 2008 and is headquartered in Beijing, China. | - |
| Bao Ping Wang | M | 63 |
Beijing Shenogen Pharma Group Ltd.
Beijing Shenogen Pharma Group Ltd. Pharmaceuticals: MajorHealth Technology Beijing Shenogen Pharma Group Co. Ltd. engages in the manufacture of icaritin drug products. It focuses on the treatment of multiple malignant tumors such as hepatocellular carcinoma, breast cancer, non-small cell lung cancer, and lymphoma. The company was founded by Kun Meng and Zhao Yi Wang on May 5, 2008 and is headquartered in Beijing, China. | 6 years |
| Yong Peng | M | 62 |
Beijing Shenogen Pharma Group Ltd.
Beijing Shenogen Pharma Group Ltd. Pharmaceuticals: MajorHealth Technology Beijing Shenogen Pharma Group Co. Ltd. engages in the manufacture of icaritin drug products. It focuses on the treatment of multiple malignant tumors such as hepatocellular carcinoma, breast cancer, non-small cell lung cancer, and lymphoma. The company was founded by Kun Meng and Zhao Yi Wang on May 5, 2008 and is headquartered in Beijing, China. | 6 years |
| Jian Xun Liu | M | 69 |
Beijing Shenogen Pharma Group Ltd.
Beijing Shenogen Pharma Group Ltd. Pharmaceuticals: MajorHealth Technology Beijing Shenogen Pharma Group Co. Ltd. engages in the manufacture of icaritin drug products. It focuses on the treatment of multiple malignant tumors such as hepatocellular carcinoma, breast cancer, non-small cell lung cancer, and lymphoma. The company was founded by Kun Meng and Zhao Yi Wang on May 5, 2008 and is headquartered in Beijing, China. | 5 years |
| Ye Yan | F | 66 |
Beijing Shenogen Pharma Group Ltd.
Beijing Shenogen Pharma Group Ltd. Pharmaceuticals: MajorHealth Technology Beijing Shenogen Pharma Group Co. Ltd. engages in the manufacture of icaritin drug products. It focuses on the treatment of multiple malignant tumors such as hepatocellular carcinoma, breast cancer, non-small cell lung cancer, and lymphoma. The company was founded by Kun Meng and Zhao Yi Wang on May 5, 2008 and is headquartered in Beijing, China. | 5 years |
| Meng Jun Xue | M | 53 |
Beijing Shenogen Pharma Group Ltd.
Beijing Shenogen Pharma Group Ltd. Pharmaceuticals: MajorHealth Technology Beijing Shenogen Pharma Group Co. Ltd. engages in the manufacture of icaritin drug products. It focuses on the treatment of multiple malignant tumors such as hepatocellular carcinoma, breast cancer, non-small cell lung cancer, and lymphoma. The company was founded by Kun Meng and Zhao Yi Wang on May 5, 2008 and is headquartered in Beijing, China. | - |
| San Guo Zhu | M | 74 |
Beijing Shenogen Pharma Group Ltd.
Beijing Shenogen Pharma Group Ltd. Pharmaceuticals: MajorHealth Technology Beijing Shenogen Pharma Group Co. Ltd. engages in the manufacture of icaritin drug products. It focuses on the treatment of multiple malignant tumors such as hepatocellular carcinoma, breast cancer, non-small cell lung cancer, and lymphoma. The company was founded by Kun Meng and Zhao Yi Wang on May 5, 2008 and is headquartered in Beijing, China. | 8 years |
| Wing Yu Leung | F | 53 |
Beijing Shenogen Pharma Group Ltd.
Beijing Shenogen Pharma Group Ltd. Pharmaceuticals: MajorHealth Technology Beijing Shenogen Pharma Group Co. Ltd. engages in the manufacture of icaritin drug products. It focuses on the treatment of multiple malignant tumors such as hepatocellular carcinoma, breast cancer, non-small cell lung cancer, and lymphoma. The company was founded by Kun Meng and Zhao Yi Wang on May 5, 2008 and is headquartered in Beijing, China. | - |
| Bing Wu | M | 50 |
Beijing Shenogen Pharma Group Ltd.
Beijing Shenogen Pharma Group Ltd. Pharmaceuticals: MajorHealth Technology Beijing Shenogen Pharma Group Co. Ltd. engages in the manufacture of icaritin drug products. It focuses on the treatment of multiple malignant tumors such as hepatocellular carcinoma, breast cancer, non-small cell lung cancer, and lymphoma. The company was founded by Kun Meng and Zhao Yi Wang on May 5, 2008 and is headquartered in Beijing, China. | 5 years |
| Lei Chen | M | 45 |
Beijing Shenogen Pharma Group Ltd.
Beijing Shenogen Pharma Group Ltd. Pharmaceuticals: MajorHealth Technology Beijing Shenogen Pharma Group Co. Ltd. engages in the manufacture of icaritin drug products. It focuses on the treatment of multiple malignant tumors such as hepatocellular carcinoma, breast cancer, non-small cell lung cancer, and lymphoma. The company was founded by Kun Meng and Zhao Yi Wang on May 5, 2008 and is headquartered in Beijing, China. | - |
| Daqing Cai | M | 59 |
Beijing Shenogen Pharma Group Ltd.
Beijing Shenogen Pharma Group Ltd. Pharmaceuticals: MajorHealth Technology Beijing Shenogen Pharma Group Co. Ltd. engages in the manufacture of icaritin drug products. It focuses on the treatment of multiple malignant tumors such as hepatocellular carcinoma, breast cancer, non-small cell lung cancer, and lymphoma. The company was founded by Kun Meng and Zhao Yi Wang on May 5, 2008 and is headquartered in Beijing, China. | - |
| Jun Feng Wang | M | 50 |
Beijing Shenogen Pharma Group Ltd.
Beijing Shenogen Pharma Group Ltd. Pharmaceuticals: MajorHealth Technology Beijing Shenogen Pharma Group Co. Ltd. engages in the manufacture of icaritin drug products. It focuses on the treatment of multiple malignant tumors such as hepatocellular carcinoma, breast cancer, non-small cell lung cancer, and lymphoma. The company was founded by Kun Meng and Zhao Yi Wang on May 5, 2008 and is headquartered in Beijing, China. | 5 years |
| Robert Eisenman | M | - |
Beijing Shenogen Pharma Group Ltd.
Beijing Shenogen Pharma Group Ltd. Pharmaceuticals: MajorHealth Technology Beijing Shenogen Pharma Group Co. Ltd. engages in the manufacture of icaritin drug products. It focuses on the treatment of multiple malignant tumors such as hepatocellular carcinoma, breast cancer, non-small cell lung cancer, and lymphoma. The company was founded by Kun Meng and Zhao Yi Wang on May 5, 2008 and is headquartered in Beijing, China. | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Zengyang Chen | M | - |
Nanjing University of Science & Technology
| 7 years |
| Jun Bao | M | 58 |
Beijing Shenogen Pharma Group Ltd.
Beijing Shenogen Pharma Group Ltd. Pharmaceuticals: MajorHealth Technology Beijing Shenogen Pharma Group Co. Ltd. engages in the manufacture of icaritin drug products. It focuses on the treatment of multiple malignant tumors such as hepatocellular carcinoma, breast cancer, non-small cell lung cancer, and lymphoma. The company was founded by Kun Meng and Zhao Yi Wang on May 5, 2008 and is headquartered in Beijing, China. | 6 years |
| Puzhang Zhou | M | 41 |
Nanjing University of Science & Technology
| 4 years |
| Jiang Hua Zou | M | 44 |
Nanjing University of Science & Technology
| 4 years |
| Zhao Ming Xu | M | 48 |
Nanjing University of Science & Technology
| 4 years |
| Cheng Chuan Lin | M | 38 |
Nanjing University of Science & Technology
| 4 years |
| Cheng Chao Wang | M | 42 |
Nanjing University of Science & Technology
| 4 years |
| Cheng Diao | M | 56 |
Nanjing University of Science & Technology
| 4 years |
| Fei Zhu | M | 42 |
University of Aberdeen
| 1 years |
| Wei Jun Gong | M | 41 |
Nanjing University of Science & Technology
| 4 years |
| Yong Yan Dai | M | 69 |
Nanjing University of Science & Technology
| 2 years |
| Jun Gang Wang | M | 41 |
Nanjing University of Science & Technology
| 4 years |
| Yun Xiang Zhu | M | 60 |
Beijing Shenogen Pharma Group Ltd.
Beijing Shenogen Pharma Group Ltd. Pharmaceuticals: MajorHealth Technology Beijing Shenogen Pharma Group Co. Ltd. engages in the manufacture of icaritin drug products. It focuses on the treatment of multiple malignant tumors such as hepatocellular carcinoma, breast cancer, non-small cell lung cancer, and lymphoma. The company was founded by Kun Meng and Zhao Yi Wang on May 5, 2008 and is headquartered in Beijing, China. | 2 years |
| Xi Ping Feng | M | 54 |
Nanjing University of Science & Technology
| 3 years |
| Feng Yang | M | 40 |
Nanjing University of Science & Technology
| 4 years |
| Yi Liu | F | 43 |
University of Aberdeen
| 2 years |
| Hua Wu | M | - |
University of Aberdeen
| 1 years |
| Dong Fang Cheng | M | 45 |
Nanjing University of Science & Technology
| 4 years |
| Chun Mei Wu | F | 43 |
Nanjing University of Science & Technology
| 4 years |
| Fan Zhu | M | 44 |
Nanjing University of Science & Technology
| 4 years |
| Hongtao Wan | M | 45 |
Nanjing University of Science & Technology
| 3 years |
| Chang Xiang Yang | M | 39 |
Nanjing University of Science & Technology
| 4 years |
| Deng Yu Chen | M | 41 |
Nanjing University of Science & Technology
| 4 years |
| Yong Cheng Wang | M | 46 |
Nanjing University of Science & Technology
| 4 years |
| Jian Wei Xing | M | 51 |
Nanjing University of Science & Technology
| 2 years |
| Yi Weng | M | 51 |
Nanjing University of Science & Technology
| 1 years |
| Peng Guo | M | 49 |
Nanjing University of Science & Technology
| - |
| Zhong Lin | M | 43 |
Nanjing University of Science & Technology
| 4 years |
| Joe Burns | M | - |
University of Aberdeen
| 1 years |
| Li Feng Zhu | M | 60 |
Nanjing University of Science & Technology
| 4 years |
| Xiaojin Yin | M | 65 |
Nanjing University of Science & Technology
| 1 years |
| Adel Ali Mohammed Hubail | M | - |
University of Aberdeen
| 3 years |
| Yi Dong Wan | M | 50 |
Nanjing University of Science & Technology
| 2 years |
| Ibrahim Hassan | M | - |
University of Aberdeen
| 1 years |
| Shu Jiang | M | 45 |
Nanjing University of Science & Technology
| 4 years |
| Barry Leaper | M | - |
University of Aberdeen
| 4 years |
| Xiao Yu Wu | F | 60 |
Nanjing University of Science & Technology
| 4 years |
| Jun He | M | 55 |
Nanjing University of Science & Technology
| 1 years |
| Jian Cheng | M | 53 |
Nanjing University of Science & Technology
| 1 years |
| Jiao Jiao Shen | F | 42 |
Nanjing University of Science & Technology
| 4 years |
| Lin Xu | M | 53 |
Nanjing University of Science & Technology
| 1 years |
| Shao Juan Chen | F | 46 |
Nanjing University of Science & Technology
| 4 years |
| Cong Min Tang | M | - |
Nanjing University of Science & Technology
| 4 years |
| Li Biao Chen | M | 42 |
Nanjing University of Science & Technology
| 4 years |
| Bing Qian | M | 51 |
Nanjing University of Science & Technology
| 1 years |
| Xin Huang | M | 42 |
Nanjing University of Science & Technology
| 4 years |
| Xin Wang | F | 40 |
Nanjing University of Science & Technology
| 3 years |
| Guo Jun Bao | M | 50 |
Nanjing University of Science & Technology
| 4 years |
| Xian Jun Li | M | 52 |
Nanjing University of Science & Technology
| 4 years |
| Wei Lü | M | 46 |
Nanjing University of Science & Technology
| 4 years |
| Da Qing Cai | M | 59 |
Beijing Shenogen Pharma Group Ltd.
Beijing Shenogen Pharma Group Ltd. Pharmaceuticals: MajorHealth Technology Beijing Shenogen Pharma Group Co. Ltd. engages in the manufacture of icaritin drug products. It focuses on the treatment of multiple malignant tumors such as hepatocellular carcinoma, breast cancer, non-small cell lung cancer, and lymphoma. The company was founded by Kun Meng and Zhao Yi Wang on May 5, 2008 and is headquartered in Beijing, China. | 3 years |
| Ou Yang | M | 46 |
Nanjing University of Science & Technology
| 4 years |
| Ya Dong Guan | M | 52 |
Nanjing University of Science & Technology
| 1 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| China | 67 | 90.54% |
| United Kingdom | 7 | 9.46% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Lei Zhu
- Personal Network
